Citigroup maintains Buy on Ultragenyx Pharma, lifts price target
Citigroup maintained a Buy rating on Ultragenyx Pharma and raised its price target to $32.00 per share from $31.00, per Benzinga.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.